以肝星状细胞为靶标的抗肝纤维化治疗进展  

Progress of Anti-hepatic Fibrosis Therapy Targeting Hepatic Stellate Cells

作　　者：陈飞龙 赵岩 杨玉霞[1] 陈翔[1] 卢娟娟[1] CHEN Feilong;ZHAO Yan;YANG Yuxia;CHEN Xiang;LU Juanjuan(Department of Gastroenterology,Gansu Provincial People's Hospital,Lanzhou,Gansu Province,730000 China)

机构地区：[1]甘肃省人民医院消化科,甘肃兰州730000

出　　处：《系统医学》2024年第2期189-193,共5页Systems Medicine

基　　金：甘肃省自然科学基金(23JRRA1300)。

摘　　要：肝纤维化是指慢性肝脏疾病发展过程中,肝细胞被反复破坏再生,导致细胞外基质在肝脏中过度沉积的结局。肝星状细胞(Hepatic Stellate Cell, HSC)是损伤肝脏的纤维化形成过程中主要的细胞类型,且有部分细胞因子参与。目前,临床中防治肝纤维化的重要途径就是抑制HSC的增殖、激活,促进HSC凋亡。本文就以HSC作为靶标的抗肝纤维化治疗方案展开综述。Hepatic fibrosis is the end result of repeated destruction and regeneration of hepatocytes during the devel⁃opment of chronic liver diseases,leading to excessive deposition of extracellular matrix in the liver.Hepatic stellate cell(HSC)is the main cell type in the fibrosis formation process in the injured liver,and some cytokines are involved.Currently,an important way to prevent and control liver fibrosis in the clinic is to inhibit the proliferation and activa⁃tion of HSC and promote HSC apoptosis.In this paper,we review the anti-hepatic fibrosis therapeutic regimen with HSC as the target.

关 键 词：肝星状细胞 靶标 肝纤维化 治疗进展 

分 类 号：R575.2[医药卫生—消化系统]